iLet Bionic Pancreas

Beta Bionics Faces Securities Fraud Suit Over iLet Pump Disclosures

Los Angeles – September 10, 2026 -- DJS Law Group has reminded shareholders of a class action lawsuit filed against Beta Bionics, Inc. (NASDAQ: BBNX) alleging violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The suit covers investors who purchased BBNX shares between July 30, 2025 and February 24, 2026, with a lead plaintiff filing deadline set for November 3, 2026.

Complaint alleges Beta Bionics downplayed FDA findings on its iLet insulin pump

The complaint centers on the iLet Bionic Pancreas insulin pump, Beta Bionics' sole commercialized product. After the company disclosed that the FDA had issued a Form 483 following a manufacturing facility inspection, defendants allegedly told investors the agency's observations were limited to complaint-reporting criteria and did not reflect underlying device problems.

Schall, Brown & Schwartz Files Securities Fraud Suit Against Beta Bionics

Los Angeles – – September 10, 2026 -- Schall, Brown & Schwartz LLP has filed a federal securities class action against Beta Bionics, Inc. (NASDAQ: BBNX), alleging the company misled investors about FDA findings tied to its iLet Bionic Pancreas insulin pump. The case, Holtzman v. Beta Bionics, Inc. et al., No. 2:26-cv-09999, is pending in the U.S. District Court for the Central District of California.

Class period spans July 2025 to February 2026 amid disputed FDA findings

The class covers purchasers of Beta Bionics common stock between July 30, 2025 and February 24, 2026. Investors face a November 3, 2026 deadline to seek appointment as lead plaintiff.

Beta Bionics Faces Class Action Over iLet Insulin Pump Disclosures

San Diego – September 10, 2026 -- Robbins LLP has filed a securities class action against Beta Bionics, Inc. (NASDAQ: BBNX) on behalf of investors who purchased common stock between July 30, 2025 and February 24, 2026, alleging the company misrepresented the safety and commercial viability of its iLet Bionic Pancreas insulin pump.

FDA warning letter contradicts prior company statements on device complaints

The complaint alleges that in October 2025, Beta Bionics disclosed an FDA Form 483 but told investors the issue was limited to complaint-reporting classification, not device safety, and that only minor customer complaints needed backfiling. Plaintiffs allege the FDA had in fact identified device malfunctions causing dangerously high insulin dosing and hypoglycemic events, with complaints numbering in the thousands and hundreds involving life-threatening incidents requiring medical intervention.